Keep your expectations in check.

Dec 10 (Reuters) - Pfizer will cut over 200 jobs in Switzerland as part of its multi-year cost reduction program, Bloomberg ...

After beefing up the target of its global cost-savings drive once again, Pfizer is continuing to see its plan through with ...

Pfizer has entered into a global collaboration and license agreement with YaoPharma for the development, manufacturing and commercialization of YP05002, a small-molecule GLP-1 receptor agonist ...

Pfizer Inc.’s Tukysa, when given as part of the initial treatment for an advanced form of breast cancer, delayed tumor growth ...

The FDA is reportedly considering the addition of high-level warning labels to COVID vaccines, a move that some experts say ...

Pfizer’s RIF and severance practices face scrutiny in a Dec. 8 New Jersey filing by a former physician challenging OWBPA ...

With $6 billion left in firepower, Pfizer is planning transactions in the hundreds of millions to the low-billions range, ...

Dec 9 (Reuters) - Pfizer said on Tuesday it entered into an exclusive licensing agreement with YaoPharma, a subsidiary of ...

Pfizer (PFE) is reiterated as a Buy, supported by the world's largest drug pipeline and trading below intrinsic value, ...

Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a $0.43 first-quarter 2026 dividend on the ...

Pfizer's oral HER2 inhibitor Tukysa looks poised to find a new role as first-line maintenance therapy for HER2-positive ...